|Articles|April 16, 2007
Fixed-combination products offer option for greater IOP-lowering
Fixed-combination therapies may have a role in glaucoma management when monotherapy reduces IOP but not sufficiently to reach the target level, said Luca Rossetti, MD, professor of ophthalmology, University of Milan, Italy.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
Dompé's NAION program selected for FDA Commissioner’s National Priority Voucher Program
3
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
4
AAO 2025: Diana Do, MD, reviews the real-world use of aflibercept 8 mg
5